Home  /  Resource Library  /  Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

Results of a study examining brentuximab vedotin combined with radiation therapy for first line treatment of Pediatric Hodgkin lymphoma.